Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director · President and CEO | February 18, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed March 03, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,232,087 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-18 · Grant · Acquired 188,856 · Balance 4,323,398 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Row 2 · 2026-02-18 · Tax withholding · Disposed 91,311 · Balance 4,232,087 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 115,450 | $4.04 | $466,418.00 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2021 Filed Jul 21, 2021 00:45 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 24,313 | $0.99 | $24,069.87 |
DisclosureSEC source: 0001661181-21-000062 · edgar.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 00:43 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 6,265 | $19.83 | $124,234.95 |
DisclosureSEC source: 0000899243-21-014957 · doc4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,542 Read SEC document |
| April 01, 2021 Filed Apr 9, 2021 00:34 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 7,890 | $19.83 | $156,458.70 |
DisclosureSEC source: 0000899243-21-015444 · doc4a.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,917 F1 · shares: This Form 4/A is being filed to correct an administrative error in the reported number of securities forfeited for tax witholding purposes and the amount of securities beneficially owned following the transaction. F1 · balance_after: This Form 4/A is being filed to correct an administrative error in the reported number of securities forfeited for tax witholding purposes and the amount of securities beneficially owned following the transaction. Read SEC document |
| February 18, 2021 Filed Feb 19, 2021 01:34 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 16,663 | $12.85 | $214,119.55 |
DisclosureSEC source: 0001661181-21-000025 · edgar.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,807 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.62 to $13.265, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 01:34 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 11,174 | $13.82 | $154,424.68 |
DisclosureSEC source: 0001661181-21-000025 · edgar.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,470 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.76 to $13.90, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 01:34 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 78,201 | $13.30 | $1,040,073.30 |
DisclosureSEC source: 0001661181-21-000025 · edgar.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,644 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.75, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 02:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 111,406 | $13.12 | $1,461,646.72 |
DisclosureSEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,219 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.71 to $13.67, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:34 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 395,289 | $0.00 Strike: $13.68 | $0.00 |
DisclosureSEC source: 0001661181-21-000025 · edgar.xml · derivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,289 Underlying: Class A Common Stock · 395,289 shares Expires 2031-02-16 F6 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 01:34 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 51,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000025 · edgar.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,845 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 02:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 33,391 | $13.77 | $459,794.07 |
DisclosureSEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,625 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.58 to $14.02, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 02:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 77,938 | $12.96 | $1,010,076.48 |
DisclosureSEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,016 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.565 to $13.53, inclusive. The reporting person undertakes to provide to ORGO, any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 02:57 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 69,127 | $13.82 | $955,335.14 |
DisclosureSEC source: 0001661181-21-000013 · edgar.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,954 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $14.22, inclusive. The reporting person undertakes to provide to Organogenesis Holdings Inc. ("ORGO"), any security holder of ORGO, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 11:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 580,842 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0001661181-20-000008 · edgar.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,842 Underlying: Class A Common Stock · 580,842 shares Expires 2030-04-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 11:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 88,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-20-000008 · edgar.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 486,081 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning April 1, 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:56 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 397,900 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001661181-20-000002 · edgar.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 397,900 shares Expires 2020-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 23:56 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionCommon Stock | 397,900 | $1.70 | $676,430.00 |
DisclosureSEC source: 0001661181-20-000002 · edgar.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 1,637,631 | Not disclosed Strike: $0.99 | Not disclosed |
DisclosureSEC source: 0001661181-18-000032 · edgar.xml · derivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637,631 Underlying: Common Stock · 1,637,631 shares Expires 2024-12-08 F7 · price: Received in connection with the Merger in exchange for an option to acquire 806,715 shares of common stock of Organogenesis for $2.00 per share. F6 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on December 8, 2015. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 664,804 | Not disclosed Strike: $0.99 | Not disclosed |
DisclosureSEC source: 0001661181-18-000032 · edgar.xml · derivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 664,804 Underlying: Common Stock · 664,804 shares Expires 2024-08-21 F5 · price: Received in connection with the Merger in exchange for an option to acquire 327,490 shares of common stock of Organogenesis for $2.00 per share. F1 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 704,410 | Not disclosed Strike: $0.99 | Not disclosed |
DisclosureSEC source: 0001661181-18-000032 · edgar.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,410 Underlying: Common Stock · 704,410 shares Expires 2023-07-25 F4 · price: Received in connection with the Merger in exchange for an option to acquire 347,000 shares of common stock of Organogenesis for $2.00 per share. F3 · derivative.exercise_date: The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2016. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 00:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 397,900 | Not disclosed Strike: $1.70 | Not disclosed |
DisclosureSEC source: 0001661181-18-000032 · edgar.xml · derivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,900 Underlying: Common Stock · 397,900 shares Expires 2019-07-01 F2 · price: Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 196,010 shares of common stock of Organogenesis for $3.45 per share. F1 · derivative.exercise_date: 100% of the shares subject to this option are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.